<DOC>
	<DOC>NCT01908816</DOC>
	<brief_summary>The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.</brief_summary>
	<brief_title>An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Glaucoma, Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active choroidal neovascularization (CNV) Active macular edema (ME) Rubeosis iridis/neovascular glaucoma. Proliferative diabetic retinopathy requiring vitrectomy. wet Agerelated macular degeneration pathologic myopia pseudoxanthoma elasticum diabetic macular edema retinal vein occlusion &lt; 18 years of age History of hypersensitivity to ranibizumab Use of any systemic antiangiogenic drugs 3 months before inclusion Women of childbearing potential and Pregnant or nursing (lactating) women. Active or suspected ocular infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>